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Background: Growing evidence suggests that epigenetic mechanisms of gene regulation may play a role in
susceptibilities to specific toxicities and adverse drug reactions. MiRNAs in particular have been shown to be
important regulators in cancer and other diseases and show promise as predictive biomarkers for diagnosis and
prognosis. In this study, we characterized the global kidney miRNA expression profile in untreated male and female
F344 rats throughout the life span. These findings were correlated with sex-specific susceptibilities to adverse renal
events, such as male-biased renal fibrosis and inflammation in old age.
Methods: Kidney miRNA expression was examined in F344 rats at 2, 5, 6, 8, 15, 21, 78, and 104 weeks of age in
both sexes using Agilent miRNA microarrays. Differential expression was determined using filtering criteria of ≥1.5
fold change and ANOVA or pairwise t-test (FDR <5%) to determine significant age and sex effects, respectively.
Pathway analysis software was used to investigate the possible roles of these target genes in age- and sex-specific
differences.
Results: Three hundred eleven miRNAs were found to be expressed in at least one age and sex. Filtering criteria
revealed 174 differentially expressed miRNAs in the kidney; 173 and 34 miRNAs exhibiting age and sex effects,
respectively. Principal component analysis revealed age effects predominated over sex effects, with 2-week miRNA
expression being much different from other ages. No significant sexually dimorphic miRNA expression was observed
from 5 to 8 weeks, while the most differential expression (13 miRNAs) was observed at 21 weeks. Potential target
genes of these differentially expressed miRNAs were identified.
Conclusions: The expression of 56% of detected renal miRNAs was found to vary significantly with age and/or sex
during the life span of F344 rats. Pathway analysis suggested that 2-week-expressed miRNAs may be related to
organ and cellular development and proliferation pathways. Male-biased miRNA expression at older ages correlated
with male-biased renal fibrosis and mononuclear cell infiltration. These miRNAs showed high representation in renal
inflammation and nephritis pathways, and included miR-214, miR-130b, miR-150, miR-223, miR-142-5p, miR-185, and
miR-296*. Analysis of kidney miRNA expression throughout the rat life span will improve the use of current and
future renal biomarkers and inform our assessments of kidney injury and disease.
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Growing evidence suggests that epigenetic mechanisms
of gene regulation may play a role in susceptibilities
to specific renal diseases, toxicities, and adverse drug
reactions. MicroRNAs (miRNAs) have been shown to
be dysregulated in many renal pathologies [1,2]. For ex-
ample, miR-193a has been identified as a potent regula-
tor of focal segmental glomerulosclerosis (FSGS), a
disease impacting the glomeruli [3]. In FSGS, podocyte
function is severely disrupted by miR-193a inhibition of
Wilms tumor 1/WT1, an important transcription factor
in podocyte homeostasis. Furthermore, in diabetic con-
ditions, expression levels of miR-195 and miR-29 have
been shown to be elevated and reduced, respectively, in
podocytes where they play a role in apoptosis and fibro-
sis [4]. The requirements of miRNAs in renal podocyte
and glomerular development have also been demon-
strated [5]. MiRNAs have been shown to have both posi-
tive and negative impact on kidney function. Complete
oblation of miRNA function by deleting the miRNA pro-
cessing gene Dicer in mouse podocytes reveals deficient
podocyte homeostasis, reduced nephrogenesis, and other
glomerular abnormalities that ultimately lead to lethality
in young mice [6]. This suggests crucial roles of miRNA
regulation in podocyte function that positively impact
total kidney function. Similarly, miRNAs have been shown
to function in response to drug-induced kidney injury.
MiR-151 knockout mice have recently been used to dem-
onstrate miR-151’s protection against cisplatin-induced
kidney injury [7]. Further evidence pointed to miR-151’s
protective effects being mediated via targeted suppression
of c-Fos, a key regulator of apoptotic signaling [8]. These
protective effects suggest miRNAs play a role in mediating
key kidney functions; however, blocking miRNA function
via Dicer knockout in proximal tubule cells showed pro-
tective effects against acute kidney injury [9]. Thus, mech-
anisms for both beneficial and deleterious roles of miRNA
function in the kidney remain to be understood fully.
The rat model is often used in toxicology for assess-
ment of drugs and other chemicals. However, little is
known about the global expression patterns of miRNAs
in various organs throughout the life span of the rat and
the role they play in development and disease. MiRNAs
show promise as predictive biomarkers for diagnosis and
prognosis in a variety of tissues [10-14]. For example,
nine miRNAs (miR-21, miR-20a, miR-146a, miR-199a-
3p, miR-214, miR-192, miR-187, miR-805, and miR-194)
have been identified in C57BL/6 mice as promising bio-
markers of kidney injury after renal ischemia reperfusion
injury (IRI) [15]. These miRNAs were shown to respond
independent of lymphocyte infiltration, suggesting a
kidney-specific response. Furthermore, three circulating
plasma miRNAs (miR-16, miR-320, and miR-210) have
been identified in acute kidney injury (AKI) patients aspotential renal biomarkers [16]. MiR-210 in particular
shows promise as a strong, independent prognostic bio-
marker of survival in AKI patients. Therapeutic targeting
of miRNAs by antagomiRs to reduce adverse effects
and disease states has also been successfully shown
[17,18]. For example, anti-miR-192 has been used to de-
crease glomerular fibrosis in mouse models of diabetic
nephropathy [19].
Sex differences in nondiabetic renal disease develop-
ment and progression have been shown by several stud-
ies in humans [20-22] and in rodents [23]. Generally,
males show greater susceptibility for various renal dis-
eases (including adult FSGS, membranous nephropathy,
and immunoglobulin A nephropathy) than females. Sex
hormones appear to play a crucial role in imparting pro-
tective or predisposing effects [24]. The sex bias in sus-
ceptibility between males and females is less clear in
diabetic renal disease [25,26]. Several reports suggest in-
creased susceptibility of females to acute kidney injury
and renal toxicity [27-29]. However, male susceptibilities
to metal-induced nephrotoxicity and obesity-related ad-
verse kidney effects have been demonstrated in in vivo
models [30,31].
Advances have been made in characterizing cellular and
molecular processes involved in various kidney functions;
however, the molecular mechanisms responsible for age
and sex differences and their potential impact on bio-
marker development are not well understood. Previous
studies have demonstrated substantial sex differences in
kidney messenger RNA (mRNA) expression in rodents
[32,33], which may influence sexually dimorphic adverse
events. Examination of miRNA regulation will further ex-
pand our understanding of the sex differences observed.
While several miRNAs have previously been shown to ex-
hibit sex specificity in expression and function in other tis-
sues [34], there are no comprehensive studies that have
examined miRNA sex bias in the kidney [35]. We investi-
gated whether epigenetic mechanisms of gene regulation,
such as changes in miRNA expression, are present in the
kidney that may underlie age- and sex-specific susceptibil-
ities to adverse renal events. Our findings show notable
differences in miRNA expression that may inform our un-




Male and female Fischer 344 rats were obtained from the
National Center for Toxicological Research rat breeding
colony and maintained as previously described [33,36].
Rats used in the present study were sacrificed at 2, 5, 6, 8,
15, 21, 52, 78, and 104 weeks of age. Female animals were
not synchronized for estrous cycle. Fischer 344 rats were
used due to their frequent use for in-life bioassays in
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proved by the National Center for Toxicological Research
(NCTR) Institutional Animal Care and Use Committee.
Rats were housed two to a cage in polycarbonate cages
with hardwood chip bedding; temperature was maintained
at 23°C with a relative humidity of approximately 50%.
Animals were euthanized by carbon dioxide asphyxiation
and sacrificed at the same circadian time of day. Sections
of the kidneys were collected from rats aged 52, 78, and
104 weeks for histological examination and placed in 10%
neutral buffered formalin. Standard paraffin embedding,
sectioning, and hematoxylin and eosin staining were per-
formed before histopathological examination by a staff
board-certified pathologist. Histological pathology scores
range from 0 to 4, representing: none (0), minimal (1),
mild (2), moderate (3), or marked (4) severity. Two end-
points were evaluated: renal fibrosis and renal mononuclear
cell infiltration. All pathology findings are available in
Additional file 1. A subset of the kidney pathology data
was previously published [37]. Sex differences in histo-
pathological severity scores were evaluated for statistical
significance at 52, 78, and 104 weeks using a Mann–Whitney
U test (also known as Wilcoxon Rank-Sum test). There
were 8 to 16 animals per group and p values <0.05 were
considered significant.
RNA isolation
Whole kidneys from independent animals were ground to a
powder in liquid nitrogen. Total RNA, including the small
RNA fraction, was isolated from a 30-mg aliquot of ground
kidney tissue powder and homogenized as previously de-
scribed [33] using Qiagen miRNeasy Mini Kit (Qiagen Inc.,
Valencia, CA, USA) according to the manufacturer’s
protocol. The yield of the extracted RNA was determined
spectrophotometrically (Nanodrop-1000, Thermo Scien-
tific, Wilmington, DE, USA) by measuring the optical
density at 260 nm. RNA quality was evaluated using the
RNA 6000 LabChip and Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). RNA samples with
RNA integrity numbers (RINs) greater than 8.0 were used
for microarray experiments with an average RIN of 8.5 for
all samples.
Microarray experiments
Genome-wide miRNA expression microarray experi-
ments (n = 5 for 2-, 5-, 6-, 15-, 21-, and 78-week males
and 6-, 15-, 78-, and 104-week females; n = 4 for 8- and
104-week males and 2-, 5-, 8-, and 21-week females)
were completed for a total of 74 microarrays. Single
color (Cy3) Agilent Rat 8 × 15 K miRNA microarrays
and reagents were used according to the manufacturer’s
protocols (Agilent Technologies, Santa Clara, CA, USA)
using 100 ng of total RNA. An Agilent one-color spike-
in kit was used as a positive control to measure bothlabeling and hybridization efficiency. Labeled probe was
purified using BioRad Micro Bio-Spin 6 columns (BioRad
Life Science Research, Hercules, CA, USA), according to
the manufacturer’s protocol. Hybridized microarrays were
scanned using the Agilent High Resolution C Scanner
(Agilent Technologies, Santa Clara, CA, USA) according
to the manufacturer’s protocol. The images were analyzed
using Agilent’s Feature Extraction software. Expression
data were deposited in Gene Expression Omnibus (Acces-
sion ID GSE64842).
Microarray data analysis
Microarray TIFF images were analyzed using Agilent
Feature Extraction (FE) software for preliminary quality con-
trol assessments which utilized labeling and hybridization
spike-ins. The FE quality control evaluation metrics were
within the ranges designated “good” or “excellent” for all
microarrays. The raw (median) intensities were calculated
in FE to generate a single value (total gene signal) for each
miRNA. Individual array files (74 total) were uploaded in
ArrayTrack [38,39], the Food and Drug Administration’s
relational database for genomic data storage, processing,
analysis, and visualization that was created at the NCTR.
ArrayTrack is freely available at: http://www.fda.gov/
ScienceResearch/BioinformaticsTools/Arraytrack/default.
htm. A single file containing the raw intensities of miR-
NAs from all arrays was exported from ArrayTrack. An
intensity value of 0.1 represented miRNAs that were not
expressed. Intensity values of 0.1 were replaced by the
minimum intensity value (1.39) across all the arrays. This
file containing the raw intensities of all arrays was used as
the input file for further data pre-processing in SAS 9.1.3
(SAS Institute Inc., Cary, NC, USA) to remove controls
and target redundancy. Out of 15,744 array features, 2,204
features representing controls were removed, resulting in
13,540 features measuring sample miRNAs (677 unique
miRNA × 20 replicates per miRNA). Redundant replicates
(containing redundant values) were removed, resulting in
a dataset containing 677 unique miRNAs. Next, those fea-
tures which were not expressed (intensity = 1.39) in any of
the arrays were discarded, leaving 311 unique features,
which were expressed in at least one array. Raw intensity
data for all arrays were transposed and transformed to
log2 values, and normalization (75th percentile) was per-
formed on the 311 miRNAs. Relative expression values
(REVs) for each microarray feature/spot were calculated
by taking individual animal normalized log2 intensity
values divided by the averaged normalized intensities from
all ages. Subsequently, a generalized linear model proced-
ure (proc glm) in SAS was used to perform ANOVA to
measure statistical significance of group differences using
REVs as the dependent variable. Age effects were deter-
mined independently for males and females. Magnitude of
group differences were calculated as the difference of log2
Table 1 Histopathology average severity score
Age
(weeks)
Fibrosis Mononuclear cell infiltration
Female Male p value Female Male p value
52 0.1 0.7 0.025* 0.3 1 0.009*
78 0.5 2.11 0.001* 1 1.9 0.002*
104 1.5 2.43 0.014* 1.63 2.5 0.006*
*p < 0.05, Mann–Whitney U test comparing female and male groups at each age.
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equaled the fold change between groups. MiRNAs were
considered differentially expressed by age when the
ANOVA FDR was <5%, and age group differences were
significant (p < 0.05) and showed ≥1.5 fold change differ-
ence between age groups. Sex effects were determined
using pairwise t-test with FDR <5% and ≥1.5 fold change
difference between sexes of the same age. There were 174
miRNAs that were differentially expressed by age or sex.
Log2 REV values for all groups were subsequently
exported as anti-log. Principal component analysis (PCA)
and k-means clustering were performed in ArrayTrack on
log2 normalized expression values. Group average REVs,
principal component 1 (PC1) loading values, and k-means
clusters for each differentially expressed miRNA (DEM)
are shown in Additional file 2.
miRNA functional analysis
Specific DEMs were analyzed using Ingenuity Pathway
Analysis (IPA, http://www.ingenuity.com/) software. DEMs
exhibiting an age effect were prioritized for pathway ana-
lysis using loading values from the PCA. Principal compo-
nent 1 (PC1) represented primarily age-related differences
in expression; therefore, the loading values for PC1 were
rank ordered (Additional file 2). Those miRNAs having the
most influence on PC1 variation ranked at the top and bot-
tom of the distribution. Loading values with absolute value
of ≥0.07 were included in gene lists for functional analysis.
All DEM gene lists analyzed are shown in Additional file 3.
Ingenuity pathways were considered significant if they ex-
hibited a p value <1 × 10−4 and at least three molecules
were represented. Top networks with scores >20 were also
considered in functional analysis. The expression of three
miRNAs associated with fibrosis (miR-142-5p, miR-150,
miR-223) was correlated with histopathology fibrosis sever-
ity scores. Individual animal fibrosis severity scores of fe-
male and male animals (Additional file 1) from 78 and
104 weeks of age (n = 4 or 5 per group, total of 18 compari-
sons for each correlation) were matched with their respect-
ive miRNA expression data (normalized intensities), and
Pearson correlation coefficients and respective p values
were generated; p values <0.05 were considered significant.
IPA infrequently associated a rat miRNA with a miRNA
family gene name represented by a human miRNA of dif-
ferent name (e.g., rno-miR-363 is affiliated with miR-92a in
gene list mapping); thus, miR-363 is associated with miR-
92a in the Ingenuity knowledgebase for purposes of func-
tional analysis.
Taqman qPCR experiments
For each sample, 5 ng of total RNA was used in a 15 μl
reverse transcription reaction using Taqman miRNA Re-
verse Transcription Kit (Life Technologies, Grand Island,
NY, USA) and miRNA-specific primers according to themanufacturer’s instructions. The reverse transcription
product (1.33 μl) was used in a 20 μl Taqman MicroRNA
Taqman Assay reaction with predesigned miRNA-specific
probes, according to the manufacturer’s instructions.
Taqman PCR was conducted in MicroAmp Optical 384-
well reaction plates (Applied Biosystems, Waltham, MA,
USA) on an ABI 7900HT real-time PCR detection system.
The expression level of each sample for each miRNA was
standardized to U6 small nuclear RNA (snRNA), to con-
trol for differences in RNA loading, quality, and comple-
mentary DNA (cDNA) synthesis using the ΔΔCt method.
For graphing purposes, the log2 relative expression levels
are shown, such that the expression level of the mean ex-
pression for Taqman PCR (n = 5) and microarray data
(n = 4 or 5) is equal to zero. A Pearson correlation coeffi-
cient (R) was calculated for each gene comparing Taqman
and microarray relative expression with age.
Results
Sex- and age-associated renal histopathology
Histological examination of kidney tissues at 52, 78, and
104 weeks of age revealed moderate to marked mono-
nuclear cell infiltration (average severity scores of 1, 1.9,
and 2.5 at 52, 78, and 104 weeks, respectively) in males
compared to only mild to moderate infiltration (average
severity scores: 0.3, 1, and 1.6 at 52, 78, and 104 weeks,
respectively) in females (Table 1 and Additional file 1). A
similar trend was observed in the observations of renal
fibrosis; males exhibited greater average severity than fe-
males at 52, 78, and 104 weeks (0.1, 0.5, and 1.5 in fe-
males and 0.7, 2.1, and 2.4 in males, respectively).
Images illustrating these histopathological findings were
previously published [33]. These results revealed sex-
biased occurrences of renal pathologies associated with
aging in male rats.
Sex- and age-associated differential miRNA expression
Of the 677 unique miRNAs present on the Agilent
microarray, 311 were expressed at least once at any age
in either sex. Those miRNAs whose expression changed
with age were identified by ANOVA with FDR <5% with
an additional requirement that the expression level dif-
ference between age groups be at least 1.5 fold. One
hundred seventy-three miRNAs showed age-associated
differential expression (Additional file 2); 131 miRNAs
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lap). Comparing male expression with female expression
at each age using a t-test and FDR <5% showed sexual
dimorphism in the expression of 34 miRNAs; 33 were
differentially expressed by both age and sex. One DEM
(miR-125a-5p) exhibited only a sex effect. Therefore, a
total of 174 differentially expressed miRNAs (DEMs), by
age or sex, were identified in the kidney (Figure 1).
These 174 DEMs were then used in PCA to identify
relationships between the kidney miRNA profiles of ani-
mals within a group and between groups (Figure 2). PC1
appears to capture the variability in the expression data
(35.1%) due to age, as age groups (distinguished by
color) are distributed from young age to old age (left to
right) along the PC1 axis. Variability in the expression
data due to sex within age groups are not clearly ob-
served except in 2-week animals, where females exhibit
a slightly “older” profile than males. PC2 appears to rep-
resent interindividual variability of data from animals
within the same age group. PC3 shows age differences
that exist between the very young and very old com-
pared to 5-, 6-, and 8-week-old animals. PC2 and PC3
accounted for 12.1% and 8.3% of the variability within
the expression data, respectively. Within PC1, variability
between animals of the same group appears to be less
than variability between different age groups. That is,
animals within age groups cluster more closely with each
other than with other age groups. Among all groups, age
showed a larger effect than sex, based upon larger vari-
ability represented by PC1, and no evident mapping of
sex effect to the other principal components. WithinFigure 1 Differential expression of miRNAs was calculated for
age effects (ANOVA FDR <5%, post hoc test for multiple
comparisons (p < 0.05), and fold change ≥1.5 between any two
age groups; males and females analyzed independently) and
sex effects (pairwise t-test, FDR <5% and ≥1.5 fold change
between average female and male animals at each age).PC1, the eight age groups clustered into three subgroups:
2-week animals, 5- to 8-week animals, and 15- to 104-
week animals. However, animals from 15, 21, and 78 weeks
of age did show slightly greater interindividual variability
(primarily along the PC2 axis) than the other age groups
while still maintaining general continuity between neigh-
boring age groups along PC1. The 2-week-old animals
showed the most separation from other age groups. How-
ever, all other age subgroups displayed a contiguous pat-
tern, with neighboring age groups extending consecutively
along the PC1 axis. Animals from the 5- to 8-week-old
subgroup also showed separation from the 2-week and
15- to 104-week animals along the PC3 axis.
To visualize the expression patterns of individual DEMs,
k-means clustering was utilized to group miRNAs into
common patterns (Figure 3). The number of k-means
clusters was set at 10 as a modest estimation of the diver-
sity present within the data. DEMs tended to cluster ac-
cording to normalized intensity level; highly expressed
miRNAs clustered with other highly expressed miRNAs
and lowly expressed miRNAs with other low expressers.
This clustering behavior likely occurred due to the relative
stability of expression of all miRNAs throughout the life
span. MiRNAs that are expressed at a certain level at an
early age tend to maintain that expression level through-
out the life span, in both sexes. Members of the let-7 fam-
ily of miRNAs (7a, 7c, 7f, and 7b) exhibit the highest
expression levels throughout the life span. Slight differ-
ences in expression are evident at 2 weeks for some miR-
NAs, especially those in clusters 4, 6, and 7.
The distribution of sex differences is not uniform
across the life span (Figure 4). Eight miRNAs were
expressed differently between males and females at two
weeks of age, while none were found at 5, 6, and 8 weeks
of age. Sex differences occurred from 15 to 104 weeks of
age, with the most (13 miRNAs) observed at 21 weeks of
age. Of the 34 miRNAs showing sex different expression,
17 exhibited female-biased expression (female expression >
male expression, Table 2), while 17 exhibited male-biased
expression (male expression > female expression, Table 3).
The miRNAs showing the most consistent sex difference in
expression (sex differences in at least three contiguous age
groups) were miR-421* and miR-499. MiR-208* showed
the highest fold change difference between sexes with fe-
male expression approximately 16 and 21-fold higher than
male expression at 15 and 21 weeks of age, respectively.
Other female-biased miRNAs showing large differences in
expression included miR-139-3p (5-fold), miR-501 (6-fold),
and miR-421* (2.6-fold). Several miRNAs also exhibited
substantial male-biased expression, including miR-142-5p
(7.8-fold), miR-130b (5.9-fold), and miR-206 (4.6-fold).
Examples of the expression profiles of miRNAs that
change with age and/or sex are shown in Figures 5
and 6. Female-biased miRNA expression is illustrated by
Figure 2 One hundred seventy-four miRNAs meeting threshold criteria (ANOVA FDR <5%, post hoc test for multiple comparisons
(p < 0.05), and fold change ≥1.5) for differential expression by age or sex were included in principal component analysis. Each sphere
represents the expression profile of one animal plotted in three-dimensional space according to the top three principal components. Spheres of
the same color are animals of the same age group (weeks of age). Spheres with black vertices indicated females while those without represent
males (n = 4 or 5).
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which showed female-biased expression at 15 and
21 weeks. MiR-499 also exhibited female bias at 78 weeks
of age and miR-421* at 78 and 104 weeks of age. Male-
biased miRNA expression was observed for miR-206 and
miR-135a (Figure 5D-E), both of which showed higher
expression in males at 21 weeks of age. Male-biased
expression at older ages was observed for miR-142-5p
(Figure 5F) with significant difference at 104 weeks of
age. Age-specific changes in miRNA expression were
found for miR-296*, miR-196a (Figure 5H-I), miR-181a,
miR-214, miR-363, and miR-18a (Figure 6D-G) which
showed high expression at 2 weeks of age in both sexes,
followed by low and decreasing expression at all subse-
quent ages. The miRNAs that showed highest expression
during middle or young adult ages (15 and 21 weeks)
were miR-192 and miR-194 (Figure 6B,H), both of which
show steady increase in expression at early ages, that
peak at 15 and 21 weeks of age, before decreasing at
older ages. MiRNAs exhibiting old-age expression in-
cluded miR-21, miR-146a (Figure 6A,C), and membersof the miR-29 family (miRa/b/c), which exhibit low ex-
pression at young age with increasing expression at older
ages (78 and 104 weeks) (Figure 5J-L).
Six miRNAs were selected for verification by Taqman
quantitative PCR, and the expression profiles are shown in
Figure 7 along with the profiles from microarray analysis.
Statistically significant sex differences were confirmed for
miR-183, miR-204, and miR-142-3p (Figure 7B-D). Signifi-
cant age differences in the expression of miR-34a, miR-
223, and miR-130b (Figure 7A,E,F) were confirmed by
qPCR. Pearson correlation coefficients were calculated for
each miRNA, comparing qPCR and microarray data. Cor-
relations ranged from r = 0.77 to r = 0.95 with an average
correlation of 0.87, suggesting good agreement between
the two methods in measuring miRNA expression.
Functional analysis of differentially expressed miRNAs
MiRNAs displaying the most prominent age and sex ef-
fects were further examined for functional analysis to de-
termine potential biological roles these miRNAs might be
playing in the kidney. Prominent age-affected miRNAs
Figure 3 Differentially expressed miRNAs (174 miRNAs) were clustered in 10 k-means clusters. Ten clusters were chosen as an estimate of
the number of large-scale expression patterns within the life span. As most miRNA expression changes are very subtle, miRNAs generally clustered
according to normalized expression level.
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Figure 2 suggests that PC1 represents age-associated
differences in miRNA expression among the sample
groups. Those miRNAs with the highest PC1 loading
values (absolute values ≥0.07) have the largest influence
on the age-related profile and were thus selected forAge  (wk)





Figure 4 The number of miRNAs exhibiting a sex difference in
expression (pairwise t-test, FDR <5%, and fold change ≥1.5)
was calculated for each age. Groups of 5-, 6-, and 8-week-old rats
exhibited no sex differences in miRNA expression, while 21-week-old
rats showed the highest number.functional analysis. The PC1 loading values for all 174
differentially expressed miRNAs are shown in Additional
file 2. Thirty-nine miRNAs had loading values > |0.07|.
The miRNAs with the most negative loading values in
PC1 were those that were generally most highly expressed
in 2-week-old rats with decreasing or no expression at
subsequent ages. Seventeen DEMs exhibited this pattern
and thus were analyzed as young age-expressed miRNAs.
Conversely, positive loading values in PC1 generally repre-
sented miRNAs showing increasing expression with age,
with highest expression at 78 and 104 weeks of age.
Twenty-two DEMs represented old age-expressed miR-
NAs. Thus, the young age effect (2-week-old expression,
17 miRNAs) and old age effect (78- and 104-week-old ex-
pression, 22 miRNAs) miRNAs were analyzed using In-
genuity Core Analysis (Additional file 3, Table 4). MiRNAs
associated with young age expression showed the highest
enrichment for pathways involved in renal inflammation/
nephritis (miR-130b, miR-363, miR-296*) and cancer
(miR-214, miR-130b, miR-18a, miR-181a, miR-363, miR-
196a). In total, 15 IPA subcategories including the term
“cancer” showed significant enrichment (at least three
molecules with p value <1 × 10−4) among young age-
expressed miRNAs. Old age-associated miRNAs showed
enrichment in pathways related to endocrine system
disorders (miR-129-1, miR-375, miR-223, miR-664,
Table 2 The 17 female-biased miRNAs








bias2 weeks 5 weeks 6 weeks 8 weeks 15 weeks 21 weeks 78 weeks 104 weeks
miR-421* 1.0 1.0 1.2 1.4 2.1 1.6 2.6 2.0 2.6 4 F > M
miR-499 1.6 1.0 1.2 1.4 2.2 2.4 1.9 1.5 2.4 3 F > M
miR-208* 1.1 1.3 1.0 2.0 16.3 21.8 2.0 1.2 21.8 2 F > M
miR-139-3p 0.7 1.9 0.8 3.5 1.0 5.0 1.6 4.2 5.0 2 F > M
miR-501 6.0 0.6 1.5 0.6 4.4 0.4 7.3 0.8 7.3 1 F > M
miR-29c 2.0 1.0 0.9 0.9 1.0 0.9 1.1 1.2 2.0 1 F > M
miR-33 2.0 1.0 1.0 0.7 0.7 0.7 1.1 1.1 2.0 1 F > M
miR-29b 2.0 1.1 1.0 0.9 1.0 0.9 1.1 1.3 2.0 1 F > M
miR-183 0.9 0.9 1.6 1.7 1.9 1.4 1.1 0.8 1.9 1 F > M
miR-375 1.6 1.0 1.0 1.4 1.8 1.5 1.4 1.1 1.8 1 F > M
miR-29a 1.7 1.1 0.9 1.0 1.1 0.9 1.2 1.1 1.7 1 F > M
miR-3545-3p 1.6 1.1 0.9 0.8 0.9 1.0 1.2 1.6 1.6 1 F > M
miR-34c 1.2 0.9 1.5 1.7 1.6 1.5 0.5 0.6 1.6 1 F > M
miR-129-2* 1.4 1.1 0.8 1.8 1.6 1.2 1.7 1.6 1.6 1 F > M
miR-192 1.4 0.9 0.9 0.9 1.0 0.9 1.4 1.6 1.6 1 F > M
miR-29c* 1.6 1.0 0.9 1.0 1.1 0.9 1.2 1.3 1.6 1 F > M
miR-210 1.1 1.1 1.0 1.1 1.5 1.4 1.5 1.5 1.5 1 F > M
aItalicized values indicate differential expression by sex.
bSex difference according to pairwise t-test, FDR 5%, and fold change ≥1.5.
Table 3 The 17 male-biased miRNAs








bias2 weeks 5 weeks 6 weeks 8 weeks 15 weeks 21 weeks 78 weeks 104 weeks
miR-130b 1.5 1.0 1.2 1.6 3.1 2.0 2.3 5.9 5.9 2 M > F
miR-204 1.1 1.0 1.3 1.3 1.6 2.0 1.1 1.2 2.0 2 M > F
miR-142-5p 0.9 0.7 1.0 0.9 1.2 4.0 3.3 7.8 7.8 1 M > F
miR-206 0.9 0.7 0.9 1.3 2.1 4.6 1.1 0.7 4.6 1 M > F
miR-142-3p 0.6 1.0 1.0 1.4 1.5 1.4 2.4 2.1 2.1 1 M > F
miR-135a 0.7 0.8 1.0 0.9 1.6 2.1 0.7 0.8 2.1 1 M > F
miR-223 0.9 1.1 1.0 1.0 1.1 1.3 1.6 1.9 1.9 1 M > F
miR-296* 1.7 0.7 1.0 0.9 0.9 0.5 0.7 0.7 1.7 1 M > F
miR-505 1.2 1.1 1.3 1.0 1.2 1.6 1.1 1.1 1.6 1 M > F
miR-150 0.9 0.9 1.0 0.9 1.0 1.0 1.2 1.6 1.6 1 M > F
miR-199a-5p 1.1 1.0 1.0 1.0 0.9 1.0 1.4 1.6 1.6 1 M > F
miR-22* 1.0 1.1 1.1 1.3 1.3 1.6 1.0 1.1 1.6 1 M > F
miR-455* 1.1 1.1 1.1 1.2 1.6 1.5 1.0 1.0 1.5 1 M > F
miR-125a-5p 1.2 1.0 1.0 1.1 1.2 1.5 0.9 1.0 1.5 1 M > F
miR-214 1.2 1.0 1.0 0.9 1.0 1.1 1.2 1.5 1.5 1 M > F
miR-185 0.9 1.0 1.1 1.2 1.2 1.5 0.9 0.9 1.5 1 M > F
miR-181b 1.2 0.9 1.2 1.1 1.2 1.5 1.1 1.0 1.5 1 M > F
aItalicized values indicate differential expression by sex.
bSex difference according to pairwise t-test, FDR 5%, and fold change ≥1.5.
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Figure 5 Plots of individual miRNAs (microarray data) exhibiting sex and age differences in expression are shown (n = 4 or 5). A, B, and
C show miRNAs exhibiting female-biased miRNA expression; D, E, F, and G show male-biased miRNAs; H and I show young age expressed
miRNAs; and J, K, and L show old age expressed miRNAs. Bars represent normalized intensity values per age group; blue and red colors represent
male and female data, respectively. Asterisks indicate ages where sex difference in expression is statistically significant (t-test, FDR <5%).
Kwekel et al. Biology of Sex Differences  (2015) 6:1 Page 9 of 16miR-29b, miR-34a), cancer (miR-223, miR-29b, miR-375,
miR-96), and cellular movement/invasion of cells (miR-29b,
miR-29c, miR-7a, miR-96, miR-34a, miR-375).
In a similar manner, the predominant sex-affected DEMs
were selected based upon differential expression between
sexes at any age (FC > 1.5, t-test and FDR <5%). Sex-biased
miRNAs were represented by 17 female-biased and 17male-biased miRNAs from Tables 2 and 3. Female-biased
miRNAs were characterized by enrichment for pathways
associated with organismal injury and abnormalities/
nonobstructive azoospermia (miR-29b, miR-29c, miR-33,
miR-499), endocrine system disorders (miR-129, miR-183-
3p, miR-29b, miR-375, miR-33), and cancer (miR-183-5p,
miR-192, miR-210). Male-biased miRNA expression was
Figure 6 Plots of individual miRNAs (microarray data) exhibiting sex and age differences in expression are shown (n = 4 or 5). A, B, C,
H, and I show middle to late age expressed miRNAs; D, E, F, and G show young age expressed miRNAs. E and I also show miRNAs exhibiting
significant sex differences. Bars represent normalized intensity values per age group; blue and red colors represent male and female data,
respectively. Asterisks indicate ages where sex difference in expression is statistically significant (t-test, FDR <5%).
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miR-214, miR-181b, miR-199a, miR-150, miR-135a,
miR-142-3p, miR-142-5p, miR-185), hematological dis-
ease (miR-22*, miR-142-3p, miR-142-5p, miR-150, miR-
181b), and renal inflammation/nephritis (miR-130b,
miR-223, miR-150, miR-142-5p, miR-296*, miR-185-3p)
(Additional file 2).
Discussion
Age effects more prevalent than sex effects during rat
life span
The global evaluation of miRNAs in the rat kidney re-
vealed 311 miRNAs expressed at one or more ages in ei-
ther sex during the rat life span. This is roughly half of the
total 677 miRNAs present on the Agilent rat microarray,
suggesting a substantial role for miRNA regulation of gene
expression within the kidney. Because the samples werederived from whole, ground kidneys, it is not possible to
assign expression of these miRNAs to specific substruc-
tures of the kidney, such as the medulla or cortex. Follow-
up studies will be necessary to identify the different kidney
cell types making contributions to the expression profiles.
Of the 311 expressed miRNAs, 174 of them (56%) showed
significant change in expression between ages or sexes (at
least a 1.5 fold difference in expression and p value <0.05).
These changes in miRNA expression manifested them-
selves generally in three age subgroups according to PCA,
consisting of young, middle, and old age groups. The
young subgroup (2 weeks old) showed the largest differ-
ence from all other subgroups and also showed slight dif-
ference between males and females, whereas all other
subgroups showed little to no sex difference in miRNA ex-
pression. These findings suggest that in our study, age in-
fluences basal miRNA expression more than sex for most
Figure 7 Select miRNAs exhibiting sex and age differences were verified by Taqman qPCR. A, E, and F show age related changes in
miRNA expression; B, C, and D show sex related changes in expression. MiRNA expression relative to the mean expression level (relative
expression log2) is shown on Y axis. Microarray and qPCR data are represented by dotted and solid lines, respectively. Male and female are
indicated by blue and red colors, respectively. The Pearson correlation coefficient (R) was calculated between microarray and qPCR data for each
miRNA. Asterisks indicate ages where statistical difference in expression between sexes exists according to pairwise t-test (p < 0.05) for each
age in qPCR data.
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by the fact that the number of DEMs exhibiting sex differ-
ences (34 DEMs) was lower than those showing age differ-
ences (173 DEMs). Despite the number of miRNAs
showing differential expression, k-means cluster analysis
revealed that the expression profiles generally grouped
according to expression level (Figure 3). MiRNAs of acertain expression level typically maintained that level
for the majority of the life span in both sexes, showing a
relatively constant expression pattern compared to dif-
ferentially expressed genes (mRNA) [33]. Evaluation of
how sex-biased miRNAs are distributed across the age
groups (Figure 4) showed a noticeable gap in sex-biased
expression between 2 and 15 weeks of age; ages at
Table 4 Pathway analysis results
Analysis Gene lista Pathway analysis resultsb Number of miRNAs p value/score
Age effects Young age expression
(17 miRNAs)
Top tox func: renal inflammation/renal nephritis 3 3.68E-05
Disease and bio func: organismal inj./abnorm. (nonobstruct azoospermia) 5 2.55E-08
cancer (cervical squamous cell carcinoma) 6 1.14E-07
Top network: organismal inj./abnorm., repro. syst. dis., cancer 10 27
Old age expression
(22 miRNAs)
Top tox func: N/A - -
Disease and bio func: endocrine syst. dis. (non-insul-dep. diab. mellitus) 6 1.13E-07
cancer (pancreatic ductal adenocarcinoma) 4 1.16E-07
cellular movement (invasion of cells) 6 6.20E-05
Top network: cancer, endocrine syst. dis, gastrointestinal dis. 9 22
Sex effects Female >male
(17 miRNAs)
Top tox func: N/A - -
Disease and bio func: cancer (uterine endometrioid carcinoma) 4 1.19E-09
organismal inj. and abnorm (nonobstruct azoospermia) 5 9.28E-09
endocrine syst disorder (non-insulin-dep diabetes mellitus) 6 1.11E-08
Top network: organismal injury, repro syst dis, cell death and survival 10 27
Male > female
(17 miRNAs)
Top tox func: renal inflammation/renal nephritis (lupus nephritis) 6 1.93E-10
Disease and bio func: cancer (cervical squamous cell carcinoma) 9 1.61E-18
hematological dis (nasal natural killer cell lymph) 5 1.87E-10
Top network: cancer, organismal inj & abnorm, repro system disorder 11 28
aGene lists are available in Additional file 3.
bIPA was used to identify significantly enriched pathways.
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taking place in the rat. This suggests that the more sub-
tle or fine-tuned regulation by miRNAs of gene expres-
sion may not be involved in sexually dimorphic
expression changes during this time.
Functional analysis reveals overlapping and redundant
pathways
Identifying the miRNAs that display age and sex differ-
ences was a crucial first step in elucidating the potential
roles that miRNAs may play in sexually dimorphic and
age-related susceptibilities. However, the specific meta-
bolic pathways controlled by these DEMs in the kidney
are not well understood [40,41]. In general, functional
analysis (Ingenuity) of the most predominant miRNAs
showing age and sex-specific effects resulted in pathways
and functional categories with notable overlap between
the various age and sex analysis groups (Table 4). For ex-
ample, cervical carcinoma or nonobstructive azoosper-
mia pathways occurred among the top findings in three
of the four analysis groups. The same miRNAs were fre-
quently found to populate several pathways with few
pathways exhibiting distinct, non-overlapping miRNA
lists. For example, miR-130b was found in pathways re-
lated to cancer, renal inflammation, and organismal in-
jury and abnormalities, while miR-150 was found in
both cancer and renal inflammation pathways. This maybe explained by the current, relatively immature status
of miRNA functional analysis databases and tools com-
pared to those available for gene expression (mRNA).
Despite the presence of highly ranked functional cat-
egories (according to Ingenuity p value and number of
member miRNAs) that are not readily interpretable in
the context of the kidney (e.g. cervical carcinoma, non-
obstructive azoospermia), several trends that relate to
kidney physiology were evident in the results and are
discussed below.
Young rats express proliferation-related miRNAs
One trend related to age effects was observed in the
young age expression group (17 miRNAs expressed pre-
dominantly at 2 weeks of age, Additional file 3). Func-
tional analysis for the young age miRNAs revealed
several pathways related to hyperplasia, proliferation and
cancer being over represented. More than 15 cancer-
related pathways ranked among the top findings for the
young age group and included common miRNAs: miR-
363, miR-181a, miR-130b, and miR-18a (Figures 5 and 6).
It is likely that the “cancer”-related categories from the
IPA analysis are representative of cell processes related to
hypertrophy, proliferation, or differentiation as opposed to
a disease state; especially in such young animals (2 weeks
old). MiR-363 is a member of the miR-92a family and its
2-week expression is consistent with its role in the
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organ development [42]. MiR-181a and miR-130b have
also been shown to be involved in endothelial cell prolifer-
ation [43]. MiR-18a and miR-92a are members of the
miR-17/92 cluster, the first characterized oncogenic
miRNA cluster, called oncomir-1 [44]. The cluster’s ac-
tivities in cell proliferation and tumorigenesis are well
characterized. MiR-18a targets Smad2 and Smad4, two
members of the TGF-β signaling pathway. The expres-
sion of these miRNAs early in the rat life span (2 weeks)
suggests overlapping roles in regulating cellular prolifera-
tion and differentiation during early kidney development
at 2 weeks of age that were not needed at subsequent ages,
as their expression decreases substantially.Old age-related miRNA expression
A second age-related effect involved the old age expres-
sion group (22 miRNAs with increasing expression levels
at later ages, Additional file 3). DEMs within this group
had the most influence in old age expression, based
upon highly ranked PC1 loading values. The miRNAs
showing the highest expression within this group were
three members of the miR-29 family (miR-29b, miR-29a,
and miR-29c). Each of these three showed increasing ex-
pression with age in both sexes. MiR-29 has previously
been shown to play a protective role in attenuating
CCl4-induced liver fibrosis [45]. However, renal fibrosis
observed in histopathology sections in the current study
(Table 1) was more apparent in male rats compared to
females, suggesting some other, possibly tissue-specific,
mechanisms. MiR-29b has also been shown to negatively
regulate DNA methylation via its direct targeting of
DNMT3A and DNMT3B, which are involved in de novo
DNA methylation [46]. MiR-29 family repression of
DNA methylation activities in older animals would sug-
gest multiple levels of epigenetic regulation. A second
age-affected DEM among the highest PC1 loading values
is miR-34a, which shows increasing expression with age
in both sexes (Figure 7). MiR-34a is known to target
p53-related apoptosis signaling and has been previously
shown to be upregulated in the kidney in conjunction
with cisplatin-induced renal toxicity [47]. It is not clear
how the age-related increase in miR-34a may influence
susceptibility, but its role in cell death may be a key.
Functional analysis of old age-expressed miRNAs found
pathways related to cellular movement and invasion of
cells (Table 4), which also relates to the histopathology
findings of renal mononuclear cell infiltration (Table 1),
likely in conjunction with immune response to increasing
fibrosis with old age. In general, the age-specific expres-
sion of miRNAs in the rat kidney appears to represent
pathways reflecting the developmental and aging activities
present at young and old age, respectively.Female-biased miRNA expression predominant in young
adult animals
MiRNAs that were differentially expressed between the
sexes were grouped according to either female-biased or
male-biased miRNAs. Those DEMs exhibiting female
bias (17 miRNAs, Additional file 3) included miRNAs
showing the highest fold-change differences between sexes
(miR-208*, with 21-fold change F >M) and most pro-
longed, sex-biased expression (miR-421*, at 15, 21, 78, and
104 weeks). Several female-biased miRNAs exhibited
both age and sex effects and have been associated with
proliferation, cell death, and immune function in various
cancers. For example, both miR-499 and miR-421*, which
showed the most female-biased expression at 15, 21, and
78 weeks of age (Figure 5), have been shown to regulate
proliferation and apoptosis via different cellular pathways
[48,49]. MiR-421* showed significant female-biased ex-
pression over the longest timespan in the kidney (15–104
weeks of age) (Figure 5). Interestingly, this miRNA maps
to the X chromosome and has been associated with
X-chromosome activation and imprinting [50]. MiR-183
also showed female-biased expression during middle age
(Figure 7) and has been proposed as a promising bio-
marker for early detection and prognosis of certain can-
cers including colorectal and prostate [51]. Both miR-375
and miR-223 play roles in regulating inflammation [52]
but exhibited very different, sex-biased expression in the
kidney, with miR-375 showing female-biased expression
at 15 weeks of age (Table 2) and miR-223 showing male-
biased expression at old age (Table 3 and Figure 7).
Female-biased miRNAs feature some of the most promis-
ing candidates (miR-421*, miR-499, miR-208*) to further
investigate the potential impact of sex-biased expression
of miRNAs in the kidney.
Male-biased expression of inflammation/fibrosis-related
miRNAs in old age
Sex effects in kidney miRNA expression were also found
to exhibit an equivalent number of male-biased miRNAs
(17 miRNAs, Additional file 3). Functional analysis of
male-biased DEMs showed conspicuous representation
of pathways related to renal inflammation and renal
nephritis (six miRNAs, p value 1.93 × 10−10). These six
miRNAs are miR-130b, miR-296*, miR-223, miR-142-5p,
miR-185, and miR-150. Three of these six molecules
exhibited a pattern of increasing expression with age
(miR-223, miR-150, miR-142-5p). This suggests that
renal inflammation/nephritis pathways exhibit male-
biased patterns that increase with age. This finding
agrees with the male-biased fibrosis and mononuclear
cell infiltration pattern found in male histology sections
(Table 1). Individual animal kidney fibrosis severity
scores correlated positively and significantly (p < 0.05)
with individual miR-142-5p (R= 0.526), miR-150 (R = 0.567),
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78 and 104 weeks of age. Furthermore, miR-142-5p and
miR-223, both male-biased DEMs (Figures 5 and 7), have
been previously implicated in fibrosis pathways [53],
highlighting agreement regarding the functional roles
of these miRNAs. However, the finding that the renal
inflammation/nephritis pathway was also represented in
the young age gene list (17 miRNAs, high expression at
2 weeks with decreasing expression at subsequent ages)
seems to be confounding with the hypothesis of old age
activity in this pathway. Nevertheless, the possibility of
both positive and negative activities among these pathway
members could account for the different expression pat-
terns. One of the most notable male-biased miRNAs,
miR-206 (Figure 5), has been shown to directly target cyc-
lin D1, a key regulator of cell cycle control [54]. Another
male-biased miRNA, miR-204 (Figure 7), has been shown
to directly target Sirt1, a key regulator of various meta-
bolic processes, including resistance to oxidative stress
and fibrosis [55]. Male-biased, age-associated increases in
kidney fibrosis and mononuclear cell infiltration were ob-
served by analysis of tissue sections (Table 1; Additional
file 1). Male animals had fibrosis and mononuclear cell
infiltration severity scores greater than 1.5 times those of
females at 78 and 104 weeks of age; thus, the male-biased
increase in expression of miR-204 at prior ages (15 and
21 weeks) may be linked, via downregulation of Sirt1,
to the age-associated kidney fibrosis seen in our study.
MiR-204-induced reduction of Sirt1 protein may be ex-
pected to make the kidney more susceptible to oxidative
injury. In fact, Sirt1 expression appears to protect against
ischemia/reperfusion-induced acute kidney injury [56] and
unilateral ureteral obstruction induced renal injury [57]
in mouse models. So, while male-biased miRNAs did not
exhibit the highest or most prolonged sex differences in
expression (as in the female-biased miRNAs), their sex-
biased expression could be connected to physiologically
relevant endpoints (fibrosis, inflammation).
Potential roles of kidney miRNA as biomarkers of disease
and toxicity
MiRNAs are being examined in various pathologies as
biomarkers, as well as for disease therapy [58-62], al-
though limited information is available at this time for the
kidney [63]. The miRNA showing the greatest fold-change
difference between the sexes was miR-208* which showed
approximately 21-fold higher expression in females com-
pared to males at 21 weeks of age (Table 2 and Figure 5).
MiR-208*, as well as miR-499 (Figure 5), which showed a
2.5 fold higher level in females than males at 21 weeks of
age, have been predominantly characterized in cardiac tis-
sue, as promising biomarkers of cardiotoxicity [64]. Their
role in the kidney, and particularly their notable sex-
difference in expression, requires further investigation.MiR-210, which exhibits female-biased expression (1.5
fold at 15 weeks), has been identified as a potential bio-
marker in plasma samples for predicting survivability in
AKI patients [16]. Furthermore, elevated miR-210 expres-
sion in renal carcinoma tissue is predictive of better clin-
ical outcomes for clear cell renal cell cancer patients [65].
In our study, miR-210 showed slight but statistically sig-
nificant female bias in expression, with females showing
1.5 fold higher expression than males at 15 weeks of age
(Table 2). This sex difference may contribute a slight pro-
tective effect for females against AKI or certain renal can-
cers, but further study is necessary.
A previous report characterized an miRNA expression
signature, consisting of nine miRNAs, that was specific to
ischemic reperfusion injury [15]. Of the nine miRNAs in
this IRI-specific expression signature, six showed differen-
tial expression in our study (four of which exhibited in-
creasing expression with age, including miR-21, miR-146a,
miR-192, and miR-194) (Figure 6). Although miR-21 ex-
hibited a conspicuous pattern of higher expression in
males compared to females at 78 and 104 weeks (both
ages exhibiting >1.5 fold difference), the sex difference was
not statistically significant. However, miR-214 exhibited
sex-biased increase in expression at 104 weeks, showing
1.5 fold higher expression in males than in females. These
findings suggest that age and sex differences in expression
may need to be considered when utilizing such classifiers.
Conclusions
The specific sex- and age-associated miRNAs identified in
the kidney of a rat model is an important first step in un-
derstanding the role that epigenetic mechanisms of gene
regulation might play in sex- and age-associated susceptibil-
ities. To our knowledge, this is the first presentation of glo-
bal profiles of kidney miRNA expression throughout the
entire rat life span in both sexes. Several lines of evidence,
most notably the male-biased expression of miRNAs and
their linkage to inflammation and fibrosis pathways, point
to substantial involvement of age- and sex-related miRNAs
in the male-biased renal fibrosis and mononuclear cell infil-
tration observed in our study. Additionally, developmental
roles for miRNAs expressed predominantly in very young
(2 week) animals are suggested by pathways related to can-
cer and proliferation. Further work will be required to elu-
cidate the biological impact of the sex differences observed.
However, the presence of clear age and sex differences
among many kidney miRNAs promises deeper understand-
ing of kidney biology and potential renal biomarkers.
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Additional file 1: Histopathology report. Histopathological findings
regarding kidney fibrosis and mononuclear cell infiltration for individual
animals at 52, 78, and 104 weeks of age.
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miRNAs. Relative expression values for all differentially expressed
miRNAs by age and/or sex; including maximum age group difference,
number of significant age differences, PC1 loading values, and
k-means cluster assignments. Table is sorted by absolute value of
PC1 loading values.
Additional file 3: Pathway analysis miRNA lists. Four lists of miRNAs
used for pathway analysis in IPA for evaluating age effects (young
age-expressed and old age-expressed miRNAs) and sex effects
(female-biased and male-biased miRNAs).
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